Baclofen for alcohol withdrawal
- PMID: 31689723
- PMCID: PMC6831488
- DOI: 10.1002/14651858.CD008502.pub6
Baclofen for alcohol withdrawal
Abstract
Background: Alcohol withdrawal syndrome (AWS) is a distressing and life-threatening condition that usually affects people who are alcohol dependent when they discontinue or decrease their alcohol consumption. Baclofen shows potential for rapidly reducing symptoms of severe AWS in people with alcoholism. Treatment with baclofen is easy to manage and rarely produces euphoria or other pleasant effects, or craving for the drug. This is an updated version of the original Cochrane Review first published in 2011 and last updated in 2017.
Objectives: To assess the efficacy and safety of baclofen for people with AWS.
Search methods: We updated our searches of the following databases to June 2019: the Cochrane Drugs and Alcohol Group Specialised Register, CENTRAL, PubMed, Embase, and CINAHL. We also searched registers of ongoing trials. We handsearched the references quoted in the identified trials, and sought information from researchers, pharmaceutical companies, and relevant trial authors about unpublished or uncompleted trials. We placed no restrictions on language.
Selection criteria: We included all randomised controlled clinical trials (RCTs) evaluating baclofen versus placebo or any other treatment for people with AWS. We excluded uncontrolled, non-randomised, or quasi-randomised trials. We included both parallel group and cross-over studies.
Data collection and analysis: We used standard methodological procedures expected by Cochrane.
Main results: We included four RCTs with 189 randomised participants (one RCT new for this update). None of the included studies reported the primary outcomes of alcohol withdrawal seizures, alcohol withdrawal delirium, or craving. For the comparison of baclofen and placebo (1 study, 31 participants), there was no evidence of a difference in Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar) scores in eight-hour periods from days one to five (very low-quality evidence). For the comparison of baclofen and diazepam (2 studies, 85 participants), there was no evidence of a difference in change from baseline to days 10 to 15 on CIWA-Ar scores (very low-quality evidence, meta-analysis was not performed due to insufficient data). In one study (37 participants), there was no evidence of a difference in participants with at least one adverse event (risk difference (RD) 0.00, 95% confidence interval (CI) -0.10 to 0.10; very low-quality evidence), dropouts (RD 0.00, 95% CI -0.10 to 0.10; very low-quality evidence), and dropouts due to adverse events (RD 0.00, 95% CI -0.10 to 0.10; very low-quality evidence). For the comparison of baclofen and chlordiazepoxide (1 study, 60 participants), there was no evidence of a difference in difference from baseline to nine-day decremental fixed-dose intervention: CIWA-Ar scores (mean difference (MD) 1.00, 95% CI 0.70 to 1.30; very low-quality evidence), global improvement (MD 0.10, 95% CI -0.03 to 0.23; very low-quality evidence), 14/60 participants with adverse events (RD 2.50, 95% CI 0.88 to 7.10; very low-quality of evidence), dropouts (RD 0.00, 95% CI -0.06 to 0.06; very low-quality evidence), and dropouts due to adverse events (RD 0.00, 95% CI -0.06 to 0.06; very low-quality evidence). None of the RCTs provided information on random sequence generation or allocation concealment, therefore, we assessed them at unclear risk of bias. Two RCTs were not of double-blind design and had a high risk of bias in blinding (Addolorato 2006; Girish 2016). One RCT had more than 5% dropouts with high risk of attrition bias (Lyon 2011). We could not assess reporting bias as none of the prepublished protocols were available.
Authors' conclusions: No conclusions can be drawn about the efficacy and safety of baclofen for the management of alcohol withdrawal because we found insufficient and very low-quality evidence.
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Conflict of interest statement
JL: none.
LW: none.
Figures
Update of
-
Baclofen for alcohol withdrawal.Cochrane Database Syst Rev. 2017 Aug 20;8(8):CD008502. doi: 10.1002/14651858.CD008502.pub5. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2019 Nov 6;2019(11). doi: 10.1002/14651858.CD008502.pub6. PMID: 28822350 Free PMC article. Updated. Review.
Similar articles
-
Baclofen for alcohol withdrawal.Cochrane Database Syst Rev. 2017 Aug 20;8(8):CD008502. doi: 10.1002/14651858.CD008502.pub5. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2019 Nov 6;2019(11). doi: 10.1002/14651858.CD008502.pub6. PMID: 28822350 Free PMC article. Updated. Review.
-
Baclofen for alcohol withdrawal.Cochrane Database Syst Rev. 2015 Apr 3;(4):CD008502. doi: 10.1002/14651858.CD008502.pub4. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2017 Aug 20;8:CD008502. doi: 10.1002/14651858.CD008502.pub5. PMID: 25836263 Updated. Review.
-
Baclofen for alcohol withdrawal.Cochrane Database Syst Rev. 2013 Feb 28;(2):CD008502. doi: 10.1002/14651858.CD008502.pub3. Cochrane Database Syst Rev. 2013. Update in: Cochrane Database Syst Rev. 2015 Apr 03;(4):CD008502. doi: 10.1002/14651858.CD008502.pub4. PMID: 23450582 Updated. Review.
-
Baclofen for alcohol withdrawal.Cochrane Database Syst Rev. 2011 Jan 19;(1):CD008502. doi: 10.1002/14651858.CD008502.pub2. Cochrane Database Syst Rev. 2011. Update in: Cochrane Database Syst Rev. 2013 Feb 28;(2):CD008502. doi: 10.1002/14651858.CD008502.pub3. PMID: 21249712 Updated. Review.
-
Baclofen for alcohol use disorder.Cochrane Database Syst Rev. 2023 Jan 13;1(1):CD012557. doi: 10.1002/14651858.CD012557.pub3. Cochrane Database Syst Rev. 2023. PMID: 36637087 Free PMC article. Review.
Cited by
-
Understanding the Mechanisms of Action and Effects of Drugs of Abuse.Molecules. 2023 Jun 24;28(13):4969. doi: 10.3390/molecules28134969. Molecules. 2023. PMID: 37446631 Free PMC article. Review.
-
Evaluation of Gabapentin and Baclofen Combination for Inpatient Management of Alcohol Withdrawal Syndrome.Fed Pract. 2023 Apr;40(4):128-133. doi: 10.12788/fp.0362. Epub 2023 Apr 20. Fed Pract. 2023. PMID: 37223663 Free PMC article.
-
Comparative efficacy and safety of pharmacotherapies for alcohol withdrawal: a systematic review and network meta-analysis.Addiction. 2022 Oct;117(10):2591-2601. doi: 10.1111/add.15853. Epub 2022 Mar 15. Addiction. 2022. PMID: 35194860 Free PMC article. Review.
-
Benzodiazepines: Their Use either as Essential Medicines or as Toxics Substances.Toxics. 2021 Feb 1;9(2):25. doi: 10.3390/toxics9020025. Toxics. 2021. PMID: 33535485 Free PMC article. Review.
-
Baclofen for alcohol withdrawal.Cochrane Database Syst Rev. 2017 Aug 20;8(8):CD008502. doi: 10.1002/14651858.CD008502.pub5. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2019 Nov 6;2019(11). doi: 10.1002/14651858.CD008502.pub6. PMID: 28822350 Free PMC article. Updated. Review.
References
References to studies included in this review
Addolorato 2006 {published data only}
-
- Addolorato G, Leggio L, Abenavoli L, Agabio R, Caputo F, Capristo E, et al. Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam. American Journal of Medicine 2006;119(3):276.e13‐8. - PubMed
Girish 2016 {published data only}
-
- Girish K, Vikram Reddy K, Pandit LV, Pundarikaksha HP, Vijendra R, Vasundara K, et al. A randomized, open‐label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome. Biomedical Journal 2016;39(1):72‐80. - PMC - PubMed
Jhanwar 2014 {published data only}
-
- Jhanwar A, Patidar OP, Sharma RN, Chourishi A, Jain A. A double blind study for efficacy of diazepam and baclofen in the treatment of alcohol withdrawal syndrome. Journal of Pharmaceutical and Biomedical Sciences 2014;4(6):482‐8.
Lyon 2011 {published data only}
-
- Lyon JE, Khan RA, Gessert CE, Larson PM, Renier CM. Treating alcohol withdrawal with oral baclofen: a randomized, double‐blind, placebo‐controlled trial. Journal of Hospital Medicine 2011;6(8):469‐74. - PubMed
References to studies excluded from this review
Addolorato 2002b {published data only}
-
- Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L, et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double‐blind randomised controlled study. Alcohol and Alcoholism (Oxford, Oxfordshire) 2002;37(5):504‐8. - PubMed
Addolorato 2007 {published data only}
-
- Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol‐dependent patients with liver cirrhosis: randomised, double‐blind controlled study. Lancet 2007;370(9603):1915‐22. - PubMed
Addolorato 2011 {published data only}
-
- Addolorato G, Leggio L, Ferrulli A, Cardone S, Bedogni G, Caputo F, et al. Dose–response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double‐blind, placebo‐controlled trial. Alcohol and Alcoholism (Oxford, Oxfordshire) 2011;46(3):312‐7. - PubMed
Beraha 2016 {published data only}
-
- Beraha EM, Salemink E, Goudriaan AE, Bakker A, Jong D, Smits N, et al. Efficacy and safety of high‐dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double‐blind controlled trial. European Neuropsychopharmacology 2016;26(12):1950‐9. - PubMed
Farokhnia 2015 {published data only}
Franchitto 2014 {published data only}
-
- Franchitto N, Pelissier F, Lauque D, Simon N, Lançon C. Self‐intoxication with baclofen in alcohol‐dependent patients with co‐existing psychiatric illness: an emergency department case series. Alcohol and Alcoholism (Oxford, Oxfordshire) 2014;49(1):79‐83. - PubMed
Garbutt 2007 {published data only}
-
- Garbutt JC, Flannery B. Baclofen for alcoholism. Lancet 2007;370:1884‐5. - PubMed
Garbutt 2010 {published data only}
Geisel 2016 {published data only}
-
- Geisel O, Hellweg R, Müller CA. Serum levels of brain‐derived neurotrophic factor in alcohol‐dependent patients receiving high‐dose baclofen. Psychiatry Research 2016;240:177‐80. - PubMed
Gupta 2017 {published data only}
-
- Gupta M, Verma P, Rastogi R, Arora S, Elwadhi D. Randomized open‐label trial of baclofen for relapse prevention in alcohol dependence. American Journal of Drug and Alcohol Abuse 2017;43:324‐31. - PubMed
Hauser 2017 {published data only}
-
- Hauser P, Fuller B, Ho SB, Thuras P, Kern S, Dieperink E. The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized clinical trial. Addiction 2017;112:1173‐83. - PubMed
Imbert 2015 {published data only}
-
- Imbert B, Alvarez J, Simon N. Anticraving effect of baclofen in alcohol‐dependent patients. Alcoholism, Clinical and Experimental Research 2015;39:1602‐8. - PubMed
Krupitsky 1993 {published data only}
-
- Krupitsky EM, Burakov AM, Ivanov VB, Krandashova GF, Lapin IP, Grinenko AJ, et al. Baclofen administration for the treatment of affective disorders in alcoholic patients. Drug and Alcohol Dependence 1993;33:157‐63. - PubMed
Krupitsky 1995 {published data only}
-
- Krupitsky EM, Burakov AM, Grinenko AIa, Borodkin IuS. Effect of pharmacotherapy of affective disorders on the psycho‐semantics of alcoholic patients. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova / Ministerstvo Zdravookhraneniia i Meditsinskoi Promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe Obshchestvo Nevrologov [i] Vserossiiskoe Obshchestvo Psikhiatrov 1995;95:67‐71. - PubMed
Krupitsky 2015 {published data only}
-
- Krupitsky EM, Rybakova KV, Kiselev AS, Alexeeva YV, Berntsev VA, Chekhlaty EI, et al. Double blind placebo controlled randomized pilot clinical trial of baclofen (Baclosan®) for alcohol dependence. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova / Ministerstvo Zdravookhraneniia i Meditsinskoi Promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe Obshchestvo Nevrologov [i] Vserossiiskoe Obshchestvo Psikhiatrov 2015;115:53‐62. - PubMed
Leggio 2012 {published data only}
Leggio 2013 {published data only}
Morley 2013 {published data only}
-
- Morley KC, Leung S, Baillie A, Haber PS. The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. Contemporary Clinical Trials 2013;36:348‐55. - PubMed
Müller 2015 {published data only}
-
- Müller CA, Geisel O, Pelz P, Higl V, Krüger J, Stickel A, et al. High‐dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo‐controlled trial. European Neuropsychopharmacology 2015;25:1167‐77. - PubMed
Pommier 2014 {published data only}
-
- Pommier P, Debaty G, Bartoli M, Viglino D, Carpentier F, Danel V, et al. Severity of deliberate acute baclofen poisoning: a nonconcurrent cohort study. Basic & Clinical Pharmacology & Toxicology 2014;114:360‐4. - PubMed
Ponizovsky 2015 {published data only}
-
- Ponizovsky AM, Rosca P, Aronovich E, Weizman A, Grinshpoon A. Baclofen as add‐on to standard psychosocial treatment for alcohol dependence: a randomized, double‐blind, placebo‐controlled trial with 1 year follow‐up. Journal of Substance Abuse Treatment 2015;52:24‐30. - PubMed
Rigal 2015 {published data only}
-
- Rigal L, Legay Hoang L, Alexandre‐Dubroeucq C, Pinot J, Jeunne C, Jaury P. Tolerability of high‐dose baclofen in the treatment of patients with alcohol disorders: a retrospective study. Alcohol and Alcoholism (Oxford, Oxfordshire) 2015;50:551‐7. - PubMed
Rolland 2017 {published data only}
-
- Rolland B, Auffret M, Labreuche J, Lapeyre‐Mestre M, Dib M, Kemkem A, et al. Phone‐based safety monitoring of the first year of baclofen treatment for alcohol use disorder: the BACLOPHONE cohort study protocol. Expert Opinion on Drug Safety 2017;16:125‐32. - PubMed
Simioni 2016 {published data only}
-
- Simioni N, Preda C, Deken V, Bence C, Cottencin O, Rolland B. Characteristics of patients with alcohol dependence seeking baclofen treatment in France: a two‐centre comparative cohort study. Alcohol and Alcoholism (Oxford, Oxfordshire) 2016;51:664‐9. - PubMed
References to ongoing studies
CTRI {unpublished data only}
-
- A trial to compare safety and efficacy of Baclofen and Diazepam in Alcohol Withdrawal Syndrome. Ongoing study 2011 May 29.
Additional references
Addolorato 2002a
-
- Addolorato G, Caputo F, Capristo E, Janiri L, Bernardi M, Agabio R, et al. Rapid suppression of alcohol withdrawal syndrome by baclofen. American Journal of Medicine 2002;112:226‐9. - PubMed
Airagnes 2019
-
- Airagnes G, Ducoutumany G, Laffy‐Beaufils B, Faou AL, Limosin F. Alcohol withdrawal syndrome management: Is there anything new. La Revue de Médecine Interne 2019;40:373‐9. - PubMed
Amato 2010
Amato 2011
APA 1994
-
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington (DC): American Psychiatric Association, 1994.
Bowery 1987
-
- Bowery NG, Hudson AL, Price GW. GABAA and GABAB receptor site distribution in the rat central nervous system. Neuroscience 1987;20:365‐83. - PubMed
Carter 2009
Colombo 2000
-
- Colombo G, Agabio R, Carai MA, Lobina C, Pani M, Reali R, et al. Ability of baclofen in reducing alcohol intake and withdrawal severity: I – preclinical evidence. Alcoholism, Clinical and Experimental Research 2000;24:58‐66. - PubMed
Cooney 2019
Creamer 2018
Gortney 2016
-
- Gortney JS, Raub JN, Patel P, Kokoska L, Hannawa M, Argyris A. Risk for delirium tremens in patients with alcohol withdrawal syndrome. Cleveland Clinic Journal of Medicine 2016;83:67‐79. - PubMed
GRADE 2013
-
- Schünemann H, Brożek J, Guyatt G, Oxman A, editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. Updated October 2013. gdt.guidelinedevelopment.org/app/handbook/handbook.html (accessed prior to 8 August 2017).
Higgins 2011
-
- Higgins JP, Altman DG, Sterne JA. Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Jesse 2017
Knapp 2007
Leggio 2008
-
- Leggio L, Kenna GA, Swift RM. New developments for the pharmacological treatment of alcohol withdrawal syndrome. A focus on non‐benzodiazepine GABAergic medications. Biological Psychiatry 2008;32:1106‐17. - PubMed
Lejoyeux 1998
-
- Lejoyeux M, Solomon J, Adès J. Benzodiazepine treatment for alcohol‐dependent patients. Alcohol and Alcoholism (Oxford, Oxfordshire) 1998;33:563‐75. - PubMed
Liang 2004
-
- Liang J, Cagetti E, Olsen RW, Spigelman I. Altered pharmacology of synaptic and extrasynaptic GABAA receptors on CA1 hippocampal neurons is consistent with subunit changes in a model of alcohol withdrawal and dependence. Journal of Pharmacology and Experimental Therapeutics 2004;310:1234‐45. - PubMed
Mayo‐Smith 1997
-
- Mayo‐Smith MF. Pharmacological management of alcohol withdrawal. A meta analysis and evidence‐based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA 1997;278:144‐51. - PubMed
McDonald 2008
-
- McDonald LM, Sheppard WF, Staveley SM, Sohal B, Tattersall FD, Hutson PH. Discriminative stimulus effects of tiagabine and related GABAergic drugs in rats. Psychopharmacology 2008;197:591‐600. - PubMed
Minozzi 2010
NCT02052440
-
- NCT02052440. Preventing alcohol withdrawal syndrome with oral baclofen. clinicaltrials.gov/show/NCT02052440 (first received 3 February 2014).
Rabiee 2017
Ramos 2013
Review Manager 2014 [Computer program]
-
- Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Stallings 2007
-
- Stallings W, Schrader S. Baclofen as prophylaxis and treatment for alcohol withdrawal: a retrospective chart review. Journal of Oklahoma State Medical Association 2007;100:354‐60. - PubMed
Weiss 2002
References to other published versions of this review
Liu 2010
Liu 2011
Liu 2013
Liu 2015
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous